SUVEN

Suven Life Sciences Share Price

₹118.44 -2.53 (-2.09%)

21 Nov, 2024 14:40

SIP TrendupStart SIP in SUVEN

Start SIP

Performance

  • Low
  • ₹117
  • High
  • ₹121
  • 52 Week Low
  • ₹75
  • 52 Week High
  • ₹169
  • Open Price₹121
  • Previous Close₹121
  • Volume67,013

Investment Returns

  • Over 1 Month -9.35%
  • Over 3 Month -18.27%
  • Over 6 Month + 17.85%
  • Over 1 Year + 45.86%
SIP Lightning

Smart Investing Starts Here Start SIP with Suven Life Sciences for Steady Growth!

Invest Now

Suven Life Sciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -17.7
  • PEG Ratio
  • 0.7
  • Market Cap Cr
  • 2,583
  • P/B Ratio
  • 9.6
  • Average True Range
  • 6.86
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • -3.29
  • RSI
  • 41.93
  • MFI
  • 64.61

Suven Life Sciences Financials

Suven Life Sciences Technicals

EMA & SMA

Current Price
₹118.44
-2.53 (-2.09%)
pointer
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 16
  • 20 Day
  • ₹125.88
  • 50 Day
  • ₹130.99
  • 100 Day
  • ₹129.76
  • 200 Day
  • ₹120.16

Resistance and Support

121.51 Pivot Speed
  • R3 126.58
  • R2 125.07
  • R1 123.02
  • S1 119.46
  • S2 117.95
  • S3 115.90

What's your outlook on Suven Life Sciences?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Suven Life Sciences Ltd. is a leading pharmaceutical company in India, specializing in the development of novel drug candidates and contract research services. The company focuses on CNS (central nervous system) disorders, providing innovative solutions for the global healthcare market.

Suven Life Sciences has an operating revenue of Rs. 8.41 Cr. on a trailing 12-month basis. An annual revenue growth of 49% is outstanding, Pre-tax margin of -907% needs improvement, ROE of -38% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 4 which is a POOR score indicating inconsistency in earnings, a RS Rating of 54 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 39 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Suven Life Sciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-29 Quarterly Results
2024-08-05 Quarterly Results
2024-05-06 Audited Results
2024-01-30 Quarterly Results
2023-11-04 Quarterly Results

Suven Life Sciences F&O

Suven Life Sciences Shareholding Pattern

70.27%
1.05%
0.33%
0%
22.15%
6.2%

About Suven Life Sciences

  • NSE Symbol
  • SUVEN
  • BSE Symbol
  • 530239
  • Chairman & Managing Director
  • Mr. Venkateswarlu Jasti
  • ISIN
  • INE495B01038

Similar Stocks to Suven Life Sciences

Suven Life Sciences FAQs

Suven Life Sciences share price is ₹118 As on 21 November, 2024 | 14:26

The Market Cap of Suven Life Sciences is ₹2582.9 Cr As on 21 November, 2024 | 14:26

The P/E ratio of Suven Life Sciences is -17.7 As on 21 November, 2024 | 14:26

The PB ratio of Suven Life Sciences is 9.6 As on 21 November, 2024 | 14:26

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23